12/17
08:05 am
athe
Alterity Therapeutics (NASDAQ:ATHE) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "speculative buy" rating on the stock.
Medium
Report
Alterity Therapeutics (NASDAQ:ATHE) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "speculative buy" rating on the stock.
11/12
07:43 am
athe
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference [Yahoo! Finance]
Low
Report
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference [Yahoo! Finance]
11/12
07:25 am
athe
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
Low
Report
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
11/10
07:41 am
athe
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System [Yahoo! Finance]
Medium
Report
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System [Yahoo! Finance]
11/10
07:25 am
athe
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
Medium
Report
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
10/31
07:25 am
athe
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
Low
Report
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
10/9
08:01 am
athe
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders [Yahoo! Finance]
Low
Report
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders [Yahoo! Finance]
10/9
07:25 am
athe
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Medium
Report
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
10/2
07:35 am
athe
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Low
Report
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders